Document is current
Any future updates will be listed below
-
Authors
Hone Lopez, S. https://orcid.org/0000-0001-7615-3474
Loipfinger, S. https://orcid.org/0000-0002-5571-0435
Bhattacharya, A. https://orcid.org/0000-0003-1479-0739
Jalving, M. https://orcid.org/0000-0002-9142-9050
Oosting, S. F. https://orcid.org/0000-0003-2754-6997
Hiltermann, T. J. N. https://orcid.org/0000-0002-0665-2160
de Bruyn, M. https://orcid.org/0000-0001-9819-9131
de Vries, E. G. E. https://orcid.org/0000-0002-8949-7425
de Haan, J. J. https://orcid.org/0000-0002-1629-4715
Fehrmann, R. S. N. https://orcid.org/0000-0002-7516-315X
-
Funding
Funding for this research was provided by:
UMCG Kanker Researchfonds
- License Information
-
More Information
Article History
Received: 7 June 2025
Accepted: 22 August 2025
First Online: 11 September 2025
Declarations
:
: S.H.L., S.L., A.B., R.S.N.F., and J.J.H. declare no competing interests. M.J. reports Institutional financial support for advisory boards from Pierre Fabre, Astra Zeneca, and Regeneron; all unrelated to the submitted work. J.T.N.H. reports financial support for advisory boards or DSMB from Roche, Bristol Myers Squibb, MSD, and Pfizer; institutional financial support for clinical trials or contracted research grants from Roche, Bristol Myers Squibb, and Astra Zeneca; other financial or non-financial interests as principal investigator of clinical studies for Astra Zeneca, GSK, Novartis, Merck Serono, Roche, Bristol Myers Squibb, and Amgen; all unrelated to the submitted work. S.F.O. reports Institutional financial support for advisory boards/consultancy from Bristol Myers Squibb, Genmab, Merck, Travel Congress Management B.V.; institutional financial support for clinical trials or contracted research grants from Celldex, Pfizer, Novartis, and Merck; received non-financial support from Celldex, Pfizer, Novartis; is the principal investigator of EORTC 2120 for which EORTC has received funding from Merck; and is a member of steering and safety monitoring committee of ALX Oncology (unpaid); all unrelated to the submitted work. E.G.E.V. reports Institutional financial support for advisory boards/consultancy from NSABP, Daiichi Sankyo, and Crescendo Biologics, and institutional financial support for clinical trials or contracted research grants from Amgen, Genentech, Roche, Servier, Regeneron, Bayer, and Crescendo Biologics; all unrelated to the submitted work. M.B. received grants from the Dutch Cancer Society (KWF), the European Research Council (ERC), Health Holland (HH), Mendus, BioNovion, Aduro Biotech, Vicinivax, Genmab, and IMMIOS (all paid to the institute); received non-financial support from BioNTech, Surflay Nanotec, and Merck Sharp & Dohme; is stock option holder in Sairopa; all unrelated to the submitted work.
